事件： 公司发布2024 年度及2025 年一季度报告，2024 年实现营业收入15.09 亿元（YoY+8.76%），归母净利 润2.19 亿元（YoY+13.98%），扣非净利润2.10 亿元（YoY+16.94%）；24Q4 实现营业收入4.49 亿元 （YoY+9.32%），归母净利润0.53 亿元（YoY+8.44%），扣非净利润0.5亿元（YoY+5.18%）；25Q1 实 现营业收入3.48 亿元（YoY+12.6%），归母净利润0.59 亿元（YoY+17.25%），扣非净利润0.57 亿元 （YoY+20.49%）。 点评： 1. 出海业务持续亮眼，大客户订单驱动护理、导尿线高增，国内市场短期承压。分区域看，2024 年海 外市场营收7.97 亿元（+23.7%），大客户去库存已完成、2024 年恢复常态化，贡献收入同比增长超 30%，此外公司本地化部署不断深化，欧洲、南美、东南亚等地区均实现较快增长，墨西哥生产基地建 设也在加速推进，随着泌外等创新产品的开始出海，公司海外业务增长亮眼；国内市场持续受到医疗行 业整顿影响，同时随着集采品种的逐步落地执行，内销业务暂时承压，营收6.83 亿元（ ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][9]. Core Views - The company is transitioning from low-cost to high-cost products, initiating a new phase of high growth despite facing external challenges in recent years [10][11]. - The overall profitability has significantly improved, with gross margins increasing from 43.2% in 2022 to 44.5% in 2024, despite revenue growth being impacted by external factors [2][41]. - Future growth is expected to be driven by the introduction of high-margin new products and the gradual reduction of the impact from anti-corruption measures in the domestic market [46][48]. Summary by Sections Product System Upgrade as Core Growth Driver - The company has focused on upgrading its product system across research, sales, and manufacturing, transitioning from a traditional low-value consumables company to a more innovative entity [15][16]. - R&D investment has increased from 0.42 billion in 2019 to 1.11 billion in 2024, with the R&D expense ratio rising from 4.3% to 7.4% [16][18]. Impact of External Factors on Performance - In 2023, external factors such as inventory destocking by overseas clients led to a decline in export revenue, which fell to 2.64 billion, a year-on-year decrease of 18% [1][31]. - Domestic sales were also affected by anti-corruption measures, resulting in a 15% year-on-year decline in the second half of 2023 [1][34]. Future Outlook and Margin Improvement - The report anticipates that the impact of anti-corruption will diminish, allowing for the accelerated introduction of high-margin new products, which will boost domestic sales and margins [46][48]. - The company is also expanding its overseas operations to mitigate geopolitical risks, with plans for new manufacturing facilities in Mexico and Southeast Asia [49][50]. Financial Forecast and Valuation - The projected total revenue for 2024 is 1.509 billion, with a year-on-year growth rate of 8.8%, and net profit is expected to reach 219 million, reflecting a 14% increase [4][12]. - The target price for the company's stock is set at 16 yuan, with a current price of 11.59 yuan, indicating significant upside potential [4][9].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown a recovery in overseas business growth, with a rich pipeline of products under research and orderly construction of new production capacity [1][8] - In 2024, the company achieved operating revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit attributable to shareholders of 219 million yuan, up 13.98% year-on-year [4][5] - The company is actively expanding its overseas production base in Mexico and exploring new markets in Europe, South America, and Southeast Asia [6][8] Financial Performance - In 2024, the company's domestic sales revenue was 683 million yuan, a decrease of 5.39% year-on-year, while overseas sales revenue was 797 million yuan, an increase of 23.74% year-on-year [5][6] - The company expects revenues of 1.779 billion yuan, 2.073 billion yuan, and 2.426 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 17.9%, 16.6%, and 17.0% [8][10] - The projected net profit attributable to shareholders for 2025, 2026, and 2027 is 267 million yuan, 318 million yuan, and 384 million yuan respectively, with growth rates of 21.5%, 19.1%, and 20.9% [8][10] Product Development and Capacity Expansion - The company has a diverse range of products under research, including key anesthesia products and various medical devices, with plans to enhance production capacity in both domestic and international markets [7][8] - New production facilities are being established in Zhaoqing, China, and Mexico, with the aim to complete the first phase of construction by Q1 2026 [7][8] Market Strategy - The company is focusing on refining its channel management and optimizing its distributor structure to adapt to the changing landscape of the medical consumables market [5][6] - A specialized procurement and public affairs department has been established to navigate government procurement policies and enhance competitive pricing strategies [5][6]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on the company's performance and growth potential [1][3]. Core Viewpoints - The company has ended inventory destocking with significant localization effects and is experiencing high growth in overseas markets. However, domestic sales are impacted by medical industry regulations, leading to a slowdown in growth [3]. - In 2024, the company achieved a revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit of 219 million yuan, up 13.98% year-on-year. The first quarter of 2025 saw a revenue of 348 million yuan, reflecting a year-on-year growth of 12.6% [1][3]. - The company is expanding its market presence in Mexico, Europe, and emerging markets in South America and Southeast Asia, with foreign sales revenue reaching 797 million yuan, a year-on-year increase of 23.74%, accounting for 52.82% of total revenue [3]. - The company has shown strong growth in its anesthesia and urology product lines, with revenues of 477 million yuan and 216 million yuan, respectively, while nursing and catheter products also saw significant growth [3]. Financial Summary - The company’s revenue is projected to grow from 1.753 billion yuan in 2025 to 2.438 billion yuan in 2027, with year-on-year growth rates of 16.1%, 17.6%, and 18.2% respectively [4]. - The net profit attributable to the parent company is expected to increase from 264 million yuan in 2025 to 399 million yuan in 2027, with growth rates of 20.3%, 22.9%, and 23.1% [4]. - The gross margin for 2024 was reported at 44.53%, a decrease of 1.36 percentage points year-on-year, primarily due to the higher proportion of lower-margin overseas sales [3][4]. - The company has effectively controlled expenses, leading to an increase in the net profit margin to 15.14%, up 0.4 percentage points year-on-year [3].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至本公告披露日，公司股东广州纬岳贸易咨询有限公司合计持有公司股份 15,670,200 股，占公司总股本的 5.35%，累计质押公司股份 10,180,000 股，占其所 持股份比例的 64.96%，占公司总股本的 3.48%。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日接到公司股东广州 纬岳贸易咨询有限公司（以下简称"广州纬岳"）函告，获悉其将持有的本公司部分 股份进行了延期质押，具体情况如下： 证券代码：603309 证券简称：维力医疗 公告编号：2025-029 广州维力医疗器械股份有限公司 关于股东股份延期质押的公告 一、股东股份延期质押的基本情况 2020 年 5 月 6 日，广州纬岳将其持有的公司 9,880,600 股无限售流通股质押给 国泰君安证券股份有限公司，回购期限 12 个月。详见公司 2020 年 5 月 8 日披露于 《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站（www.sse.com.cn） 的《关于股东股 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）控股子公司广州利健益 医疗器械科技有限公司（以下简称"利健益"，本公司持股占比 70%）于近日收到 广州市市场监督管理局签发的《第二类医疗器械经营备案凭证》。现将有关情况公 告如下： 一、证书主要内容 备案编号：粤穗药监械经营备20252024号 统一社会信用代码：91440115MAECXTW14D 证券代码：603309 证券简称：维力医疗 公告编号：2025-030 广州维力医疗器械股份有限公司 关于控股子公司取得医疗器械经营备案凭证的公告 企业名称：广州利健益医疗器械科技有限公司 法定代表人：张钊 利健益取得上述《第二类医疗器械经营备案凭证》后，可开展备案凭证经营范 围内的医疗器械批发业务。上述证书的取得不会对公司经营业绩产生重大影响。 三、风险提示 相关业务在实际开展过程中，可能受到外部环境和市场变化等因素影响而存在 不确定性。敬请投资者注意投资风险。 企业负责人：张钊 经营方式：批发 经营场所：广州市南沙区珠江街兴隆路1 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the report indicates a positive outlook on the company's performance and growth potential [1][3]. Core Viewpoints - The company has ended inventory destocking with significant localization effects and is experiencing high growth in overseas markets. However, domestic sales are impacted by medical industry regulations, leading to a slowdown in growth [3]. - In 2024, the company achieved a revenue of 1.509 billion yuan, a year-on-year increase of 8.76%, and a net profit attributable to the parent company of 219 million yuan, up 13.98% year-on-year [1]. - The company is expanding its production base in Mexico and exploring markets in Europe, South America, and Southeast Asia, resulting in a 23.74% year-on-year increase in foreign sales revenue, which now accounts for 52.82% of total revenue [3]. - The company’s product lines, particularly anesthesia and urology products, are showing stable growth, with revenues of 477 million yuan and 216 million yuan respectively [3]. - The company is focusing on innovation and increasing R&D investment, which is expected to enhance its product line and improve profit margins [3]. Financial Summary - The company’s total revenue for 2024 is projected to be 1.753 billion yuan, with a year-on-year growth rate of 16.1% for 2025, reaching 2.062 billion yuan in 2026 and 2.438 billion yuan in 2027 [4]. - The net profit attributable to the parent company is expected to grow from 264 million yuan in 2025 to 399 million yuan in 2027, reflecting a compound annual growth rate of 20.3% to 23.1% [4]. - The gross margin for 2024 is reported at 44.53%, with a slight decrease attributed to the higher proportion of lower-margin overseas sales [3][4]. - The company’s sales net profit margin improved to 15.14% in 2024, indicating effective cost control measures [3]. Market and Business Outlook - The company is expected to maintain a steady growth trend as domestic demand recovers and overseas markets continue to expand [3]. - The report anticipates that the introduction of new products will not only diversify the product line but also optimize the product structure, potentially enhancing profitability [3].

Group 1 - The company has three wholly-owned subsidiaries: Weili Medical Technology Development (Suzhou) Co., Ltd., WELL LEAD GLOBAL LIMITED, and Guangdong Jieshang Medical Devices Co., Ltd. [1][2][4] - Weili Medical Technology Development (Suzhou) Co., Ltd. was established in December 2004 with a registered capital of 150 million yuan, focusing on medical device research, production, and sales [1] - WELL LEAD GLOBAL LIMITED was established in February 2024 with a registered capital of 10,000 Hong Kong dollars, engaged in the trade and investment of medical and related products [2] - Guangdong Jieshang Medical Devices Co., Ltd. was established in June 2024 with a registered capital of 50 million yuan, involved in the production and sales of various medical devices [4] Group 2 - The company provides guarantees for its wholly-owned subsidiaries based on their operational funding needs, ensuring smooth business operations and promoting stable development [5][6] - The total approved external guarantee amount is not more than 850 million yuan, accounting for 45.09% of the company's latest audited net assets attributable to shareholders [6] - The company has no overdue guarantees and maintains a good credit status for its subsidiaries [6][7] Group 3 - The company plans to reappoint Huaxing Accounting Firm (Special General Partnership) as its auditor for the 2025 fiscal year [7][8] - Huaxing Accounting Firm has a history dating back to 1981 and has provided auditing services to 91 listed companies in 2024, with total audited revenue of 370.37 million yuan [8] - The audit fee for the 2024 annual report is set at 1.1 million yuan, with a potential 20% fluctuation for the 2025 audit fee [16][19] Group 4 - The company has approved the addition of a new business address in Guangzhou and plans to amend its articles of association accordingly [22][23] - The new address is located at No. 47, Guomao Avenue South, Hualong Town, Panyu District, Guangzhou [22]

广州维力医疗器械股份有限公司 2024 年度独立董事述职报告（臧传宝） 本人作为广州维力医疗器械股份有限公司（以下简称"公司"）的独立董事， 在任职期内严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独 立董事管理办法》《上海证券交易所上市公司自律监管指引第1号——规范运作》 等相关法律法规、规范性文件及《公司章程》《公司独立董事工作制度》的规定， 积极参加公司股东大会、董事会及董事会各专门委员会会议，慎重审议各项议案， 勤勉尽责，充分发挥独立董事的独立作用，切实维护了公司和全体股东尤其是中 小股东的合法权益。现将本人2024年度工作情况汇报如下： 一、独立董事的基本情况 1、工作履历、专业背景以及兼职情况 臧传宝，男，1979年出生，中国国籍，博士研究生学历。2014年1月至今在 上海市汇业（广州）律师事务所担任合伙人、主任、律师。2023年8月至今任广 州维力医疗器械股份有限公司独立董事、董事会提名委员会召集人、董事会审计 委员会和董事会薪酬与考核委员会成员。 2、独立性情况说明 作为公司的独立董事，我本人及直系亲属、主要社会关系均不在公司或其附 属企业任职；没有直接或间接持有公司已发行股份的1 ...

广州维力医疗器械股份有限公司 章程 广州维力医疗器械股份有限公司 章程 （修订稿） 二〇二五年四月 | | | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 3 | | 第三节 | 股份转让 | 4 | | 第四章 | 股东和股东大会 | 5 | | 第一节 | 股东 | 5 | | 第二节 | 股东大会的一般规定 8 | | | 第三节 | 股东大会的召集 | 11 | | 第四节 | 股东大会的提案与通知 12 | | | 第五节 | 股东大会的召开 | 14 | | 第六节 | 股东大会的表决和决议 16 | | | 第五章 | 董事会 | 22 | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 24 | | 第六章 | 总经理及其他高级管理人员 32 | | | 第七章 | 监事会 | 34 | | 第一节 | 监事 | 34 | | 第二节 | 监事会 | 34 | | 第八章 | 财务会计制度、利润分配 ...